Switch to
More onapp

How to use scorecard? Learn more

Gland Pharma Ltd

GLAND
Health CarePharmaceuticals
MidcapWith a market cap of ₹30,393 cr, stock is ranked 224
High RiskStock is 4.89x as volatile as Nifty
1,845.2524.75 (+1.36%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹30,393 cr, stock is ranked 224
High RiskStock is 4.89x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
46.14
PB RatioPB Ratio
3.82
Dividend YieldDiv. Yield
Sector PESector PE
51.91
Sector PBSector PB
5.95
Sector Div YldSctr Div Yld
0.56%

Forecast & RatingsDetailed Forecast 

67%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.

Investor PresentationView older 

Aug 7, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

20202021202220232.773.604.623.870.771.001.210.78
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.54%

See detailed holdings

Recent EventsAll events 

Trading Window-XBRL 
Announced OnMar 26, 2024

GLAND PHARMA LIMITED has informed the Exchange about Closure of Trading Window | Download

GLAND PHARMA LIMITED has informed the Exchange about Closure of Trading Window | Download

Alteration Of Capital and Fund Raising-XBRL 
Announced OnMar 25, 2024

GLAND PHARMA LIMITED has informed the Exchange regarding Allotment of Securities | Download

GLAND PHARMA LIMITED has informed the Exchange regarding Allotment of Securities | Download

Allotment of Securities 
Announced OnMar 25, 2024

Gland Pharma Limited has informed the Exchange regarding allotment of 2400 securities pursuant to ESOP/ESPS at its meeting held on March 25, 2024 | Download

Gland Pharma Limited has informed the Exchange regarding allotment of 2400 securities pursuant to ESOP/ESPS at its meeting held on March 25, 2024 | Download

See all events